Literature DB >> 7510062

Toluene embryopathy: clinical delineation and developmental follow-up.

G L Arnold1, R S Kirby, S Langendoerfer, L Wilkins-Haug.   

Abstract

OBJECTIVE: To expand the phenotype of toluene embryopathy.
METHOD: Review of case records of 35 deliveries with antenatal exposure to toluene. Six children were examined and their features are compared with previously reported cases.
RESULTS: There were three perinatal deaths. Of the survivors, review of available data revealed a high incidence of prematurity (42%), low birth weight (52%), and microcephaly (32%). Birth weight, length, and head circumference and gestational length were significantly less than a control group closely matched for gender, race, and socioeconomic status. Follow-up pediatric evaluation revealed growth retardation (46% < 5th percentile for weight, 38% < 5th percentile for height), microcephaly (46%), and developmental delays (38%). Maternal toluene abuse of 4 or more years was positively correlated with weight < 5th percentile and microcephaly in childhood. The six children examined demonstrated many previously described features of toluene embryopathy including microcephaly, narrow bifrontal diameter, short palpebral fissures, hypoplastic midface, wide nasal bridge, abnormal palmar creases, and blunt fingertips. Only one of the six children examined had antepartum exposure to alcohol as well as toluene.
CONCLUSION: In utero exposure to toluene seems to be associated with teratogenicity in the developing fetus. A preliminary picture of toluene embryopathy is now emerging.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510062

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  [Not Available].

Authors: 
Journal:  Paediatr Child Health       Date:  1998-03       Impact factor: 2.253

2.  Gestational toluene exposure effects on spontaneous and amphetamine-induced locomotor behavior in rats.

Authors:  Scott E Bowen; Michael H Mohammadi; Jeffery C Batis; John H Hannigan
Journal:  Neurotoxicol Teratol       Date:  2006-10-06       Impact factor: 3.763

3.  A cluster of hypoplastic left heart malformation in Baltimore, Maryland.

Authors:  K S Kuehl; C A Loffredo
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

4.  Alterations in rat fetal morphology following abuse patterns of toluene exposure.

Authors:  Scott E Bowen; Susan Irtenkauf; John H Hannigan; Adrianne L Stefanski
Journal:  Reprod Toxicol       Date:  2009-01-21       Impact factor: 3.143

5.  Binge toluene exposure in pregnancy and pre-weaning developmental consequences in rats.

Authors:  Scott E Bowen; John H Hannigan
Journal:  Neurotoxicol Teratol       Date:  2013-04-15       Impact factor: 3.763

Review 6.  Developmental toxicity of prenatal exposure to toluene.

Authors:  Scott E Bowen; John H Hannigan
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

7.  Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse.

Authors:  T F Haydar; R S Nowakowski; P J Yarowsky; B K Krueger
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

8.  Maternal and fetal blood and organ toluene levels in rats following acute and repeated binge inhalation exposure.

Authors:  Scott E Bowen; John H Hannigan; Susan Irtenkauf
Journal:  Reprod Toxicol       Date:  2007-06-26       Impact factor: 3.143

9.  Non-occupational exposure to paint fumes during pregnancy and risk of congenital anomalies: a cohort study.

Authors:  Dorrit Hjortebjerg; Anne-Marie Nybo Andersen; Ester Garne; Ole Raaschou-Nielsen; Mette Sørensen
Journal:  Environ Health       Date:  2012-08-14       Impact factor: 5.984

10.  Toluene disruption of the functions of L1 cell adhesion molecule at concentrations associated with occupational exposures.

Authors:  Kimberly M R White; Julia A Sabatino; Min He; Natalie Davis; Ningfeng Tang; Cynthia F Bearer
Journal:  Pediatr Res       Date:  2016-03-08       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.